Beecham's APSAC
Executive Summary
A study comparing a two minute injection of the anti-thrombosis agent APSAC with a one hour injection of intra-coronary streptokinase is now underway at 15 hospitals, including the University of Rochester and the University of Utah. Beecham states that its new clot-dissolving agent "differs from other investigational and existing drugs in that it can be administered in a single five-minute injection into a vein." In a recent Phase II dose-response study of 29 heart attack patients conducted by Victor Marder, University of Rochester, the drug dissolved coronary clots in about 60% of the patients. . . .